Literature DB >> 16189115

Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.

Christine M Johnson1, Rajesh Pandey, Sadhna Sharma, G K Khuller, Randall J Basaraba, Ian M Orme, Anne J Lenaerts.   

Abstract

We evaluated the efficacy of nanoparticle-encapsulated antituberculosis drugs administered every 10 days versus that of daily nonencapsulated drugs against Mycobacterium tuberculosis aerosol infection in guinea pigs. Both treatments significantly reduced the bacterial count and lung histopathology, suggesting that the nanoparticle drug delivery system has potential in intermitted treatment of tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16189115      PMCID： PMC1251542          DOI： 10.1128/AAC.49.10.4335-4338.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.

Authors:  Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

2.  Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Susan L Kraft; Deanna Dailey; Matthew Kovach; Karen L Stasiak; Jamie Bennett; Christine T McFarland; David N McMurray; Angelo A Izzo; Ian M Orme; Randall J Basaraba
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 3.  Pathogenesis of experimental tuberculosis in animal models.

Authors:  D N McMurray; F M Collins; A M Dannenberg; D W Smith
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

4.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors:  C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal:  Nature       Date:  2000-06-22       Impact factor: 49.962

5.  The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Authors:  Lise Brandt; Yasir A W Skeiky; Mark R Alderson; Yves Lobet; Wilfried Dalemans; Oliver C Turner; Randall J Basaraba; Angelo A Izzo; Todd M Lasco; Philip L Chapman; Steven G Reed; Ian M Orme
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.

Authors:  Anjali Sharma; Rajesh Pandey; Sadhna Sharma; G K Khuller
Journal:  Int J Antimicrob Agents       Date:  2004-12       Impact factor: 5.283

7.  A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment.

Authors:  D W Smith; V Balasubramanian; E Wiegeshaus
Journal:  Tubercle       Date:  1991-09

8.  Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Todd M Lasco; Oliver C Turner; Lynne Cassone; Isamu Sugawara; Hiroyuki Yamada; David N McMurray; Ian M Orme
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.

Authors:  Rajesh Pandey; Anjali Sharma; A Zahoor; Sadhna Sharma; G K Khuller; B Prasad
Journal:  J Antimicrob Chemother       Date:  2003-11-12       Impact factor: 5.790

10.  Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.

Authors:  Rajesh Pandey; A Zahoor; Sadhna Sharma; G K Khuller
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131
  10 in total
  13 in total

1.  Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.

Authors:  E F Young; E Perkowski; S Malik; J D Hayden; P G Durham; L Zhong; J T Welch; Miriam S Braunstein; Anthony J Hickey
Journal:  Pharm Res       Date:  2016-06-28       Impact factor: 4.200

Review 2.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

3.  Multiple M. tuberculosis phenotypes in mouse and guinea pig lung tissue revealed by a dual-staining approach.

Authors:  Gavin J Ryan; Donald R Hoff; Emily R Driver; Martin I Voskuil; Mercedes Gonzalez-Juarrero; Randall J Basaraba; Dean C Crick; John S Spencer; Anne J Lenaerts
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

4.  Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Donald R Hoff; Megan L Caraway; Elizabeth J Brooks; Emily R Driver; Gavin J Ryan; Charles A Peloquin; Ian M Orme; Randall J Basaraba; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

5.  Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.

Authors:  Anne J Lenaerts; Donald Hoff; Sahar Aly; Stefan Ehlers; Koen Andries; Luis Cantarero; Ian M Orme; Randall J Basaraba
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 6.  Nanotechnology: a focus on nanoparticles as a drug delivery system.

Authors:  Jeffrey D Kingsley; Huanyu Dou; Justin Morehead; Barrett Rabinow; Howard E Gendelman; Christopher J Destache
Journal:  J Neuroimmune Pharmacol       Date:  2006-09       Impact factor: 4.147

7.  Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin.

Authors:  Tamara Staudinger; Bernhard Redl; Ben J Glasgow
Journal:  Biochim Biophys Acta       Date:  2014-02-12

8.  Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade.

Authors:  Pamela R Hall; Brian Hjelle; David C Brown; Chunyan Ye; Virginie Bondu-Hawkins; Kathleen A Kilpatrick; Richard S Larson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment.

Authors:  Donald R Hoff; Gavin J Ryan; Emily R Driver; Cornelius C Ssemakulu; Mary A De Groote; Randall J Basaraba; Anne J Lenaerts
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung.

Authors:  Ankan Gupta; Farhan J Ahmad; Faiz Ahmad; Umesh D Gupta; Mohan Natarajan; Vishwamohan Katoch; Sangeeta Bhaskar
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.